Cancer therapy: A role for MAPK inhibitors combined with mTORC1 inhibitors

August 25th, 2008 by

admin

(Beth Zion Deaconess Medical Center) Researchers refer a previously unacknowledged difficulty visaged by mTOR inhibitors when it comes to offensive cancers.

Tags: Cancer, Face, Medical Center

Posted in Cancer |

Related posts

Comments are closed.

Recent Posts

Are the adverse effects of glitazones linked to induced testosterone deficiency?
Prevalence of abnormal glucose metabolism in atrial fibrillation: A case control study in 75-year old subjects
The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes
Metabolic syndrome according to different definitions in a rapidly developing country of the African region
Epidemiology of bone tumors in mexico city: retrospective clinicopathologic study of 566 patients at a referral institution.
Sinonasal chondromyxoid fibroma.
Festschrift Issue honoring Judah Folkman, M.D. in Lymphatic Research and Biology
Protein’s essential role in repairing damaged cells revealed
EAU 2nd Eastern Mediterranean Meeting expected to highlight cystectomy
Study links obesity to elevated risk of ovarian cancer

Categories

Archives:

Search: